Clinical Trial Update: Campath-1H + FK506 and Methylprednisolone for GVHD [Phase 2]

View source ↗

Summary

Completed Phase 2 clinical trial evaluating Campath-1H plus tacrolimus (FK506) and methylprednisolone for graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Campath-1H (alemtuzumab)
• FK506 (tacrolimus)
• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Breast Cancer, Chronic Myeloproliferative Disorders | Phase 2 | Status: COMPLETED